Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 301 - 400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 301 | 26898183 |
US |
77 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 302 | 26898191 |
US |
2 | |
Oral herpes, Condition aggravated, Periorbital dermatitis, Rash, Dermatitis atopic, Eyelid margin crusting, Injection site erythema, Injection site warmth, Injection site pain, |
||||
DUPILUMAB, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, METRONIDAZOLE, METRONIDAZOLE TOPICAL, RUXOLITINIB, PROGESTERONE, TERBINAFINE HYDROCHLORIDE, TERBINAFINE TABLETS 250 MG, |
||||
| 303 | 26898224 |
US |
1 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 304 | 26898237 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 305 | 26898242 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 306 | 26898439 |
US |
49 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 307 | 26898450 |
US |
1 | |
Injection site pain, Injection site discomfort, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 308 | 26898474 |
US |
82 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 309 | 26898478 |
US |
39 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 310 | 26898699 |
US |
69 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 311 | 26898704 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 312 | 26898711 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 313 | 26898717 |
US |
31 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 314 | 26898966 |
US |
2 | |
Road traffic accident, Arthritis, Dermatitis atopic, |
||||
UPADACITINIB, |
||||
| 315 | 26898980 |
US |
1 | |
Limb reconstructive surgery, Ankle arthroplasty, Dermatitis atopic, |
||||
UPADACITINIB, |
||||
| 316 | 26899026 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 317 | 26899032 |
US |
2 | |
Idiopathic urticaria, Dermatitis atopic, Condition aggravated, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 318 | 26899278 |
US |
6 | 2 |
Dermatitis atopic, Therapeutic response shortened, Hypersensitivity, |
||||
DUPILUMAB, |
||||
| 319 | 26899341 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, HYDROXYZINE, CETIRIZINE HYDROCHLORIDE, |
||||
| 320 | 26899759 |
US |
1 | |
Injection site mass, Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 321 | 26900072 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 322 | 26900081 |
US |
73 | 1 |
Retinal degeneration, Eye swelling, Eye pain, Skin laceration, Dermatitis atopic, Pain in extremity, Rash macular, Peripheral swelling, Dry skin, Pruritus, Erythema, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 323 | 26900100 |
US |
13 | 1 |
Dermatitis atopic, Rash pruritic, |
||||
DUPILUMAB, |
||||
| 324 | 26900376 |
US |
12 | |
Dermatitis atopic, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 325 | 26900450 |
US |
39 | 2 |
Arthropod bite, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 326 | 26900462 |
US |
||
Conjunctivitis, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 327 | 26900500 |
US |
66 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, BUSPIRONE HYDROCHLORIDE, DIAZEPAM, DIAZEPAM ORAL, DIAZEPAM ORAL SOLUTION (CONCENTRATE), GABAPENTIN, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, TESTOSTERONE, |
||||
| 328 | 26900834 |
US |
11 | 2 |
Dermatitis atopic, Pruritus, Erythema, Skin haemorrhage, |
||||
DUPILUMAB, |
||||
| 329 | 26900838 |
US |
2 | |
Skin irritation, Skin fissures, Erythema, Skin exfoliation, Pruritus, Dermatitis atopic, Therapeutic response decreased, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, FEXOFENADINE HYDROCHLORIDE, AMOXICILLIN, SACCHAROMYCES CEREVISIAE, GABAPENTIN, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, IRBESARTAN, POLYETHYLENE GLYCOL 3350, NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, NYSTATIN, NYSTATIN OINTMENT, NYSTATIN CREAM, NYSTATIN, NYSTATIN OINTMENT, NYSTATIN CREAM, DOCUSATE SODIUM 50 MG AND SENNOSIDES 8.6 MG, DOCUSATE SODIUM, SENNOSIDES, SENNOSIDES AND DOCUSATE SODIUM, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, ERGOCALCIFEROL, |
||||
| 330 | 26900899 |
US |
23 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 331 | 26900945 |
US |
60 | 2 |
Rash, Discomfort, Sleep disorder due to a general medical condition, Dermatitis atopic, Pain, |
||||
DUPILUMAB, EPINEPHRINE, ADRENALINUM, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, MONTELUKAST SODIUM, |
||||
| 332 | 26901225 |
CA |
63 | |
Pemphigoid, Rash, Dermatitis atopic, |
||||
| 333 | 26901311 |
US |
62 | 1 |
Chronic obstructive pulmonary disease, Dyspnoea, Eczema eyelids, Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 334 | 26901324 |
US |
1 | |
Cutaneous T-cell lymphoma, Condition aggravated, Pyrexia, Dermatitis atopic, Pain, Emotional disorder, Injury, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 335 | 26901397 |
US |
57 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 336 | 26901817 |
US |
30 | 1 |
Dermatitis atopic, Product prescribing error, |
||||
DUPILUMAB, |
||||
| 337 | 26901841 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 338 | 26902031 |
US |
74 | 2 |
Oral herpes, Lacrimation increased, Eye pruritus, Headache, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 339 | 26902136 |
US |
39 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 340 | 26902146 |
US |
12 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 341 | 26892070 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 342 | 26892077 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, DIVALPROEX SODIUM, PROPRANOLOL HYDROCHLORIDE, BREXPIPRAZOLE, SERTRALINE HYDROCHLORIDE, |
||||
| 343 | 26892101 |
US |
35 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 344 | 26892234 |
US |
47 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 345 | 26892241 |
US |
12 | 2 |
Eczema, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 346 | 26892286 |
US |
29 | 1 |
Stress, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 347 | 26892289 |
US |
2 | |
Dermatitis atopic, Rash macular, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 348 | 26892294 |
US |
30 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 349 | 26892539 |
US |
15 | 2 |
Dermatitis atopic, Product dose omission issue, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 350 | 26892547 |
US |
61 | 2 |
Headache, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 351 | 26892555 |
US |
2 | |
Dermatitis atopic, Exfoliative rash, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 352 | 26892813 |
US |
22 | 2 |
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE GEL USP, 1%, CLINDAMYCIN PHOSPHATE TOPICAL, TRETINOIN, PRAZOSIN HYDROCHLORIDE, ADAPALENE, ADAPLANE 0.1%, LISDEXAMFETAMINE DIMESYLATE, SPIRONOLACTONE, ROFLUMILAST, |
||||
| 353 | 26892832 |
US |
51 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 354 | 26893095 |
US |
64 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 355 | 26893438 |
US |
17 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 356 | 26893453 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 357 | 26893454 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 358 | 26893459 |
US |
45 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 359 | 26894167 |
US |
10 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 360 | 26894173 |
US |
73 | 2 |
Rash erythematous, Pruritus, Skin burning sensation, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 361 | 26894209 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 362 | 26894225 |
US |
20 | 2 |
Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 363 | 26894894 |
US |
24 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 364 | 26894936 |
US |
63 | 2 |
Rash erythematous, Skin burning sensation, Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 365 | 26894955 |
US |
2 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 366 | 26894962 |
US |
25 | 2 |
Sensitivity to weather change, Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 367 | 26895188 |
US |
23 | |
Dermatitis atopic, Product dose omission issue, Device use error, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 368 | 26895198 |
US |
77 | |
Dermatitis atopic, Pruritus, Device malfunction, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 369 | 26895244 |
US |
37 | |
Dermatitis atopic, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 370 | 26895300 |
US |
55 | |
Dermatitis atopic, |
||||
NEMOLIZUMAB-ILTO, HYDROCHLOROTHIAZIDE, LOSARTAN, |
||||
| 371 | 26895309 |
US |
16 | |
Dermatitis atopic, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 372 | 26895407 |
US |
65 | 2 |
Dermatitis atopic, Swelling, Incorrect dose administered, Product administration issue, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 373 | 26895413 |
US |
2 | |
Dermatitis atopic, Hypersensitivity, |
||||
DUPILUMAB, |
||||
| 374 | 26895783 |
US |
5 | 1 |
Sleep disorder due to a general medical condition, Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, BETAMETHASONE VALERATE, BETAMETHASONE VALERATE FOAM, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 375 | 26895797 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 376 | 26895917 |
US |
15 | |
Dermatitis atopic, Dry skin, Pruritus, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 377 | 26896107 |
US |
61 | 2 |
Dermatitis atopic, Pruritus, Therapeutic response decreased, Arthralgia, |
||||
DUPILUMAB, CYANOCOBALAMIN, ORAL SEMAGLUTIDE, |
||||
| 378 | 26896319 |
US |
40 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 379 | 26896321 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 380 | 26896573 |
US |
17 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 381 | 26896598 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 382 | 26886627 |
US |
78 | 1 |
Burning sensation, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 383 | 26886792 |
US |
35 | 2 |
Dermatitis atopic, Pruritus, Eye pruritus, |
||||
DUPILUMAB, |
||||
| 384 | 26886797 |
US |
1 | |
Dermatitis atopic, Sleep disorder due to a general medical condition, Injection site pain, Injection site rash, Psoriasis, |
||||
DUPILUMAB, |
||||
| 385 | 26886802 |
US |
23 | 2 |
Eczema, Dermatitis atopic, Injection site reaction, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 386 | 26886815 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 387 | 26887046 |
US |
21 | 2 |
Rash erythematous, Pruritus, Skin burning sensation, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 388 | 26887051 |
US |
2 | |
Dermatitis atopic, Swelling, Dry skin, |
||||
DUPILUMAB, |
||||
| 389 | 26887065 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 390 | 26887085 |
US |
2 | |
Dermatitis atopic, Rash erythematous, Pruritus, Skin burning sensation, |
||||
DUPILUMAB, |
||||
| 391 | 26887290 |
US |
65 | 1 |
Dermatitis atopic, Pustule, Condition aggravated, Pruritus, Pain, Scratch, |
||||
DUPILUMAB, |
||||
| 392 | 26887291 |
US |
8 | 2 |
Dermatitis atopic, Skin hyperpigmentation, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 393 | 26887647 |
US |
9 | 2 |
Dermatitis atopic, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 394 | 26887652 |
US |
16 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 395 | 26887916 |
US |
2 | |
Sensitivity to weather change, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 396 | 26888214 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 397 | 26888217 |
US |
73 | 2 |
Skin exfoliation, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 398 | 26888252 |
US |
8 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 399 | 26888534 |
US |
25 | 1 |
Rash, Discomfort, Product dose omission issue, Dermatitis atopic, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, |
||||
| 400 | 26888546 |
CA |
44 | 1 |
Eye infection, Ocular hyperaemia, Swelling of eyelid, Eye discharge, Skin swelling, Condition aggravated, Erythema, Condition aggravated, Skin exfoliation, Dermatitis atopic, Fear of injection, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30